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ABSTRACT
Libraries of single-stranded oligodeoxynucleotides
(ssODNs) can be enriched for sequences that specif-
ically bind molecules on naı¨ve complex biologi-
cal samples like cells or tissues. Depending on
the enrichment strategy, the ssODNs can identify
molecules specifically associated with a defined bio-
logical condition, for example a pathological pheno-
type, and thus are potentially useful for biomarker
discovery. We performed ADAPT, a variant of SE-
LEX, on exosomes secreted by VCaP prostate can-
cer cells. A library of ∼1011 ssODNs was enriched
for those that bind to VCaP exosomes and dis-
criminate them from exosomes derived from LNCaP
prostate cancer cells. Next-generation sequencing
(NGS) identified the best discriminating ssODNs,
nine of which were resynthesized and their discrim-
inatory ability confirmed by qPCR. Affinity purifica-
tion with one of the sequences (Sequence 7) com-
bined with LC–MS/MS identified its molecular target
complex, whereof most proteins are part of or asso-
ciated with the multiprotein ESCRT complex partici-
pating in exosome biogenesis. Within this complex,
YBX1 was identified as the directly-bound target pro-
tein. ADAPT thus is able to differentiate exosomes
from cancer cell subtypes from the same lineage.
The composition of ESCRT complexes in exosomes
from VCaP versus LNCaP cells might constitute a dis-
criminatory element between these prostate cancer
subtypes.
INTRODUCTION
Extracellular vesicles (EVs), or exosomes, are small lipid
vesicles∼20–1500 nm in diameter that are secreted by most
cell types into the extracellular milieu (1). Exosomes are
highly abundant in most biological fluids such as blood
plasma, saliva, cerebrospinal fluid, urine, etc. where up to
1012 exosome-particles/ml can be detected (2). Themain bi-
ological function of exosomes is thought to be in intercellu-
lar communication. Exosomes carry a variety of bioactive
molecules as cargo, from non-coding RNAs and proteins to
metabolites and multi-molecular complexes, either in their
interior or on their surface. Theirmolecular composition re-
sembles that of the parent cell from which they are derived,
which is thought to mirror the functional state of the cell,
both in healthy and diseased states (2). Exosomes from tu-
mor cells have been shown to be involved in fundamental
aspects of cancer, including angiogenesis, immune evasion,
and metastasis (3). Thus, exosomes have been described as
a rich source for characterization of the tissue of origin and
biomarker discovery due to the straightforward, minimally
invasive access to tissue-derived samples by liquid biopsy,
and because they reflect the dynamic alterations that can
occur during tumor progression (4).
A method that has been used previously for decipher-
ing proteins expressed by complex biological targets such
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as cells or tissues is ‘systematic evolution of ligands by ex-
ponential enrichment’ (SELEX) (5–7). The molecules de-
rived from this process are single-stranded nucleic acid se-
quences, called aptamers, which can fold into complex 3D
structures to bind huge varieties of target molecules ranging
from small metabolites, other nucleic acids, proteins, post-
translational modifications or multi-molecular complexes
of biomolecules. Aptamers have been identified by SELEX
on complex targets that interact with a malignant cell pop-
ulation or with malignant tissues, without a priori knowl-
edge of the recognized target (8,9). The entire process of li-
brary enrichment can be controlled at virtually every stage
because it occurs in vitro. This allows adjusting the speci-
ficity of a library for a given biological condition, by con-
ducting the enrichment process so as to preferentially en-
rich sequences that associate with condition A (e.g. disease-
related condition) and to disfavor the co-enrichment of se-
quences that associate with condition B (e.g. non disease-
related condition) by including appropriate negative selec-
tion steps. In fact, the negative selection steps even allow
the depletion of the library for sequences that bind targets
common to both conditions, leaving in principle only those
aptamers that bind to targets characteristic for the disease-
related condition. The subsequent identification of these
unknown targets by biophysical approaches such as mass
spectrometry provides a potential avenue to biomarker dis-
covery.
Recently, in a process called ‘adaptive dynamic artificial
polyligand targeting’ (ADAPT), we described the enrich-
ment of a complex library of ssODNs for sequences that
preferentially associate with formalin-fixed paraffin embed-
ded tissue of breast cancer patients and differentiate be-
tween patients that benefit from treatment with the Her2-
antagonist trastuzumab from those that did not (10). In an-
other study we employed ADAPT to enrich an ssODN li-
brary containing 1011 different sequences for binding to cir-
culating exosomes isolated from blood plasma of women
with or without breast cancer (11). A pool of synthetic ver-
sions of 2000 sequences contained in the enriched library
was then used to profile an independent set of plasma ex-
osomes from women with or without disease. The evalua-
tion of healthy women and breast cancer-positive patients
showed that ssODN polyligands distinguished between the
two groups. By aptamer-mediated affinity purification and
mass spectrometry we identified low-abundance exosome-
associated proteins and protein complexes. We also showed
that some of the ssODNs contained in the synthetic li-
brary associated with the C1Q-complex, a component of
the serum complement system, in an aptameric binding
mechanism.
In the present study, we employ ADAPT to an even more
challenging problem, namely for enriching a ssODN-library
for sequences that can distinguish between exosomes ex-
creted by two subtypes of cancer cells originating from the
same lineage. Differentiation between cancer subpopula-
tions from related tissues requires the detection of differ-
ences in the expression levels of biomolecules that often
reflect tumor heterogeneity. The two prostate cancer sub-
types, ‘vertebral cancer of the prostate’ (VCaP) and ‘lymph
node cancer of the prostate’ (LNCaP) comply with these
premises: both subtypes express prostate specific antigen
(PSA), prostatic acid phosphatase (PAP), p53 antigen and
Rb protein (ATCC.org). Differential levels of proteins in
VCaP versus LNCaP cell exosomes have been identified by
mass spectrometry (12). VCaP cells also have increased an-
drogen receptor (AR) gene copy number and show 5–10-
fold higher levels of AR RNA and AR protein compared
to LNCaP cells (13). VCaP cells also express the androgen
receptor splice variant 7 (AR-V7) associated with increased
resistance to androgen dependent therapy (ADT) whereas
LNCaP cells have undetectable levels of the variant protein
making it an ideal system to study AR-V7 splicing and its
contribution to castration resistant prostate cancer (CRPC)
progression (13) by ADAPT. Given the tumor heterogene-
ity of AR positive subtypes and their variability in response
to ADT, we employ ADAPT to examine differential analy-
sis of exosomes from these two PC sub-types with variable
levels of AR and AR-V7.
MATERIALS AND METHODS
Exosome isolation
Cell lines were purchased from American Type Cell Cul-
ture. VCaP cells were grown in DMEMmedia and LNCaP
cells were grown in RPMI media. Exosomes were isolated
from VCaP and LNCaP cells similar to The´ry et al. (14)
with small modifications. Briefly, centrifugation of the exo-
somal supernatant at 400 × g and 2000 × g was performed
to remove cell debris. The small vesicles were then collected
using centrifugal filter units with 100 000NMWL fromMil-
lipore. Applying the concentrated exosome suspension on a
30% sucrose cushion performed the final exosome purifica-
tion by ultracentrifugation at 100 000 × g. Exosome purifi-
cation was confirmed by transmission electron microscopy
(TEM, Supplementary Figure S1).
Enrichment of aptamer library on exosomes derived from
VCaP and LNCaP cells
Five rounds of SELEX were performed on VCaP and
LNCaP exosomes derived from prostate cancer cell lines
by ultracentrifugation. In order to block non-specific bind-
ing, exosomes were pre-incubated with 10 l salmon sperm
DNA (800 ng), 10 l yeast tRNA (800 ng) in 160 l ‘reac-
tion buffer’ [1 × PBS, 3 mMMgCl2, 0.5% Pluronic® F127
(Sigma), 1 mg/ml human serum albumin (HSA)] for 20 min
at 25◦C with shaking at 500 rpm. In the first step of enrich-
ment (round 1), 20 l of a diverse library of 1011 ssODNs
(5 ng) with a 35 nt random region was incubated in reac-
tion buffer with 25 g in 180 l VCaP exosomes (positive
selection: 25 g pre-incubated exosomes for 30 min at 25◦C
with rotation (final volume: 200 l). Exosomes were then
precipitated with 6% PEG8000 (precipitation protocol: 200
l 12% PEG8000 added to 200 l ODN-bound exosomes,
30 min incubation on ice, centrifuge at 16 000 × g for 10
min at 4◦C, remove supernatant, resuspend in 200 l reac-
tion buffer, centrifuge at 16 000 × g for 10 min at 4◦C), and
exosome-associated ssODNs were recovered by elution us-
ing 10 l 0.25 M NaOH, incubation for 10 min at 50◦C,
shaking for 5–10 s at 550 rpm, addition of 10l 0.25MHCl,
centrifugation at 16 000 × g for 10 min. The supernatant
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buffer. This ssODN pool was taken straight into PCR af-
ter round 1 (11), but for subsequent rounds of enrichment
(rounds 2 – 5), the eluted ssODNs from positive selection
were further incubated with 25 g LNCaP exosomes (neg-
ative selection). LNCaP exosomes were precipitated with
6% PEG8000 and then pelleted by centrifugation at 16 000
× g for 10 min. The pellet was discarded and the unbound
ssODNs from the supernatant were collected and incubated
with a fresh aliquot of 25 g VCaP exosomes. Precipita-
tion and two-step elution were again performed, with 6%
PEG8000 and 0.25 M NaOH/HCl respectively. The eluted
ssODN library was amplified by PCR, denatured to recover
ssDNA and then purified. The amplified, enriched ssODN
library was used as the starting material for the next round
of enrichment at an input of 1011 sequences. Enrichment
wasmonitored by next-generation sequencing. Libraries af-
ter each round of enrichment were amplified by PCR with
unique indexing primers for multiplex analysis by NGS on
an Illumina HiSeq2500 (Supplementary Figure S2).
Next-generation sequencing of ssODN-probed exosomes
Exosome probingwas performed by incubating 25gVCaP
and LNCaP exosomes, in duplicate, with 2 × 1010 copies
(1 ng) enriched round 5 ssODN library for 30 min at 25◦C.
Exosomes were precipitated with 6% PEG8000 and cen-
trifuged at 16 000× g for 10min. Supernatantwas discarded
and exosome pellets were resuspended in H2O. Exosome-
associated ssODNs were amplified by PCR with unique in-
dexing primers for multiplex analysis by NGS on an Illu-
mina HiSeq2500. The nine sequences shown in Figure 2B
were selected based on a combination of fold changes of at
least 4.0 and normalized counts of at least 500 for probing
on VCaP exosomes (positive samples). Normalized counts
were obtained by dividing the raw counts by the total counts
per sample and multiplying the result by the average sample
count (Supplementary Figure S3).
Quantitative PCR analysis of ssODN-probed exosomes
Exosome probingwas performed by incubating 25gVCaP
and LNCaP exosomes with 8 × 109 copies (0.4 ng) individ-
ual or pooled ssODN sequences for 30 min at 25◦C. Exo-
somes were precipitated with 6% PEG8000 and centrifuged
at 16 000× g for 10min. Supernatant was discarded and ex-
osome pellets were resuspended in H2O. After determining
the total protein recovery by the bicinchoninic acid (BCA;
Pierce® BCA protein assay kit [ThermoFisher Scientific])
assay, from each precipitation reaction three times 2 g of
exosomes were used as the input for qPCR amplification
(Accustart II Taq DNA polymerase). The total volume per
reaction was 10 l using 6 l of SYBRGreen I (Low ROX)
Master Mix qPCR reagents (PerfeCTa from QuantaBio).
qPCR was performed using MicroAmp Optical 384-well
Reaction Plate w/Barcode (Thermo/ABI/LifeTech) on the
ViiA 7 (Applied Biosystems) instrument and consisted of a
95◦C incubation for 30 s, followed by 40 cycles at 95◦C for
10 s, 60◦C for 1 min using the following primers (purchased
from IDT-Integrated DNA Technologies, HPLC purified):
5′-CTAGCATGACTGCAGTACGT-3′ (reverse) and 5′-
TCGTCGGCAGCGTCA-3′ (forward). A standard curve
consisting of the probing sequence(s) was run in duplicate,
ranging from 5 × 104 to 5 × 108 copies. NTC (no template
control) was run in duplicate. The Viia7 software (version
1.2.3) was used to analyze standard curves and quantify
binding affinity of ssODNs to VCaP and LNCaP exosomes.
Binding is expressed as the absolute recovered copies per se-
quence from 2 g of exosomes.
Affinity purification
The ssODN sequence, herein referred to as Sequence 7, and
the reverse complement of Sequence 7 (Sequence 7RC) were
synthesized with a biotin affinity tag and 15 g each of
Sequence 7 and Sequence 7RC were immobilized to 10 l
at 10 mg/ml Dynabeads®MyOne™ Streptavidin C1 beads
(ThermoFisher Scientific) by incubation in 100 l for 30
min at room temperature in 50 mM HEPES pH 8.3, 3 mM
MgCl2, 0.5 M NaCl, 0.2 mM EDTA, 0.1% Tween-20. In
addition, a no ssODN control was included in the experi-
ment. Beads were then washed and equilibrated into sam-
ple binding buffer, 1× PBS, 3 mMMgCl2. VCaP exosomes
were prepared as described for library selection and 200 g
of resuspended exosomes were incubated with 10 l of pre-
pared beads or no aptamer control beads for 30min at room
temperature with intermittent mixing. Captured exosomes
were then lysed on the bead with 1× PBS, 3 mM MgCl2,
0.5% Triton X-100 and washed two times with lysis buffer
followed by three additional washes with 1× PBS, 3 mM
MgCl2. All incubation and washing steps were carried out
using a MagMAX™ Express-96 Magnetic Particle Proces-
sor (ThermoFisher Scientific). Samples were eluted in 0.3%
TFA, 6 M urea for 10 min at 37◦C. Eluted samples were
run for 10 min on a NuPAGE™Novex™ 4–12% gradient gel
(Life Technologies) to remove any residual PEG. The gel
was stainedwith Proteosilver® silver stain plus kit (Sigma).
The entire lane (>10 kDa to the stack) was extracted and
subjected to in-gel digestion with trypsin.
Liquid chromatography mass spectrometry
Samples containing tryptic peptides were analyzed by
nanoflow reverse phase liquid chromatography using a
Dionex Ultimate 3000 RSLCnano System (ThermoFisher
Scientific) coupled in-line to a Q Exactive HF mass spec-
trometer (ThermoFisher Scientific). The nano LC system
included an Acclaim PepMap 100 C18 5 m 100A 300 m
× 5 mm trap column and an EASY-Spray C18 3 m 100A
75 m × 150 mm analytical column (ThermoFisher Sci-
entific). Peptide samples were loaded onto the trap column
and held for 5 min at a constant flow rate of 6 l/min us-
ing running solvent A, where A consisted of 0.1% formic
acid in water. Peptides were then eluted using a linear gra-
dient of 2% to 40% B in 35 min, where B consisted of ace-
tonitrile containing 0.1% formic acid. Blank samples con-
sisting of 0.1% formic acid in water were injected between
each sample and eluted with the same gradient profile as
samples. The LC system was interfaced to the Q Exactive
HF using an EASY-Spray electrospray ion source (Ther-
moFisher Scientific) and the samples were analyzed using
positive ion spray voltage set to 2.4 kV, S-lens RF level at
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operated in data-dependent acquisition mode selecting the
top 10 most intense peaks for fragmentation. MS1 survey
scans (m/z 375–1800) were acquired in the Orbitrap ana-
lyzer with a resolution of 60 000 at m/z 200, an accumula-
tion target of 3× 106, andmaximum fill time of 50 ms.MS2
scans of the 10 most intense precursor ions were collected
using a resolution of 15 000 at m/z 200, an accumulation
target of 1 × 105, and maximum fill time of 120 ms, with an
isolation window of 1.5m/z, normalized collision energy of
27, and charged state recognition between 2 and 7.Dynamic
exclusion was applied with exclusion duration of 5 s.
Data processing
Raw data files from the Q Exactive HF were analyzed us-
ing Sequest HT in the Proteome Discoverer 2.1.1.21 suite
and searched against the SwissProt Homo sapiens fasta
database (v2015-11-11, with 42 084 entries). Precursor se-
lection was set to use MS1 precursor ions with a signal to
noise threshold of 1.5. The search parameters for Sequest
HT included full tryptic specificity with a maximum of 2
missed cleavages, minimum peptide length of 6, precursor
mass tolerance of 10 ppm, and fragment mass tolerance of
0.02 Da. Set dynamic modifications searched were oxida-
tion (15.9949 Da) of methionine, lysine, and proline; car-
bamidomethyl (57.0214 Da) of histidine, lysine and cys-
teine; acetylation (42.0105 Da) of lysine and N-terminus;
phosphorylation of serine and threonine; and dimethyla-
tion (28.0532 Da) of arginine. Validation of peptide spec-
trum matches was performed using Percolator with a max-
imum delta Cn value of 0.05. False discovery rate (FDR)
estimation was performed using a decoy database from the
reverse sequences of the target database with a FDR setting
of 0.01 for high confidence peptide matches, and validation
base on q-value. High confidence proteins were accepted as
having a q-value of 0.01 or lower as determine using a 0.01
target FDR threshold. Proteins detected with a fold-change
ratio of the average precursor ion area intensity of Sequence
7/Sequence 7RC, or Sequence 7/no ssODN bead control
>2.5 were considered as proteins likely to be enriched by
Sequence 7.
Western blotting
Exosome concentrations were determined by BCA protein
assay, which we found to reproduce better than Bradford
assays. Exosomes samples (2–10 g) were resolved by
SDS-PAGE separation on 4–12% and 12% Bis–Tris gels
(Invitrogen) and transferred to nitrocellulose membranes.
Protein detection on the membrane was confirmed with
Pierce™ Reversible Protein Stain Kit for Nitrocellulose
Membranes (ThermoFisher Scientific). Immunoblotting
was carried out using the iBind™ Western Blot System
(Invitrogen) for the following primary antibodies: anti-
CHMP1B (Santa Cruz), anti-CHMP2A (Santa Cruz),
anti-CHMP2A (Abcam), anti-CHMP4B (ThermoFisher
Scientific), anti-CHMP4C (ThermoFisher Scientific),
anti-CPSF5/NUDT21 (ThermoFisher Scientific), anti-
CSPF7 (Santa Cruz), anti-CXCL11 (ThermoFisher
Scientific), anti-DNAJA2 (Abcam), anti-EEF1A2
(ThermoFisher Scientific), anti-HBA2 (ThermoFisher
Scientific), anti-LAMA3 (ThermoFisher Scientific),
anti-MVB12A/FAM125A (ThermoFisher Scientific), anti-
PTBP1 (Abcam), anti-RBM3 (Abcam), anti-RPL30 (Ab-
cam), anti-RPLP1 (ThermoFisher Scientific), anti-S100A8
(ThermoFisher Scientific), anti-SH3GL1 (ThermoFisher
Scientific), anti-Syntenin-1 (Santa Cruz), anti-VPS28
(Santa Cruz) and anti-YBX1 (Cell Signaling). Membranes
were then washed with water for 30 min. Bound antibod-
ies were detected using the enhanced chemiluminescent
SuperSignal West Femto Maximum Sensitivity Substrate
(ThermoFisher Scientific) and images were captured using
the Syngene PXi 4 imager (Syngene). Membranes were
stripped and re-probed with anti-TSG101 (Santa Cruz) for
the loading control, using Restore Western Blot Stripping
Buffer (ThermoFisher Scientific). Intensities of bands were
determined by densitometry. Intensities of bands were
determined by densitometry.
ELONA and ELISA
High binding plates (Corning) were coated overnight, shak-
ing at 4◦C, with 10 nM of the following recombinant
proteins of interest: CHMP1B (MyBioSource), CHMP2A
(MyBioSource), CHMP4B (Origene), CHMP4C (Sigma-
Aldrich), CPSF5 (Abcam), CSPF7 (LifeSpan BioScience),
CXCL11 (Novus), DNAJA2 (Abnova), EEF1A2 (Ab-
nova), HBA2 (Novus), LAMA3 (Origene), MVB12A
(Novus), PTBP1 (Abcam), RBM3 (Abcam), RPL30 (Ori-
gene), RPLP1 (Novus), S100A8 (MyBioSource), SH3GL1
(Abnova), Syntenin-1 (Abcam), VPS28 (Abcam) and
YBX1 (MyBioSource). Coating solution was removed the
next day and washed two times. Plates were then blocked
with 1× PBS, 3 mM MgCl2, 0.1 mg/ml salmon sperm
DNA/yeast tRNA, 0.01× S1 and 3%BSA (ELONA) or 5%
milk in TBS-T (ELISA), incubated at RT for 3 h. For the
ELONA, the aptamer and SA-Poly HRP were pre-mixed
for 15 min at 800 rpm, and then added to the plate for
1 h at RT. For the ELISA, the primary antibodies, same
ones used in western blotting with the exception of: anti-
CHMP4B (MyBioSource), anti-HBA2 (Santa Cruz), anti-
S100A8 (R&D systems), anti-Syntenin-1 (ThermoFisher
Scientific), were added for 1 h at RT, followed by 3×washes
and addition of the secondary antibody for 1 h at RT. Plates
were washed several times before adding the substrate solu-
tion (TMB; R&D Systems) for 5 min and stopped with stop
solution (2 N H2SO4). Plates were read at 450/540 nm cor-
rection on a plate reader (Biotek).
RESULTS
In vitro selection of ssODN libraries targeting VCaP exo-
somes
Positive selection against isolated exosomes fromVCaP cells
was performed by incubation of the exosomes with a library
of 1011 different ssODNs for 30 min. Unbound ssODNs
were partitioned from the bound ones by precipitating ex-
osomes with polyethylene glycol (PEG) as described pre-
viously for plasma exosomes (11). Bound ssODNs were
eluted from precipitated exosomes by denaturation and am-
plified by asymmetric PCR to complete the first selection
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positive selection on exosomes from VCaP cells
negative selection on exosomes from LNCaP cells
C
Round 1: 
Rounds 2-5:  positive   negative  positive selection  PCR
positive selection  PCR
Figure 1. Selection scheme of ssODNs that bind to VCaP exosomes but not to LNCaP exosomes. (A) A highly diverse library of 1011 ssODNswas subjected
to five rounds of positive selection. (B) Schematic for the negative selection cycle introduced at round 2 for the remaining selection. Aftermixing of exosomes
with ODN library the unbound DNAwas removed by precipitating exosomes and bound ssODNs by polymer. (C) Summary of the succession of selection
rounds against exosomes from VCaP and LNCaP prostate cancer cell lines.
enrichment of ssODNs associated with molecular features
specific for VCaP cell exosomes, each subsequent selection
cycle consisted of the following steps: the ssODNs eluted
from the precipitated VCaP cell exosomes were incubated
for 30 min with exosomes purified from LNCaP cells in
a negative selection step (Figure 1B), LNCaP exosomes
were PEG-precipitated, and the supernatant was subjected
to another positive selection step on exosomes from VCaP
cells, after which the eluted VCaP exosome-bound ssODNs
were PCR amplified (Figure 1). This procedure was re-
peated until enrichment round 5 was completed (Figure
1C). The eluted ssODNs from each selection round were
amplified by PCR, and then subjected to next generation
sequencing (NGS) to monitor enrichment (Supplementary
Figure S2). As expected, an increase in copies per sequence
species across the five subsequent rounds of enrichment was
determined.
Identification and verification of VCaP exosome-binding
ssODNs
To identify individual ssODN sequences that preferentially
bound to VCaP exosomes, we used the enriched round 5
library to probe the binding of ssODNs to exosomes iso-
lated from VCaP cells in comparison to exosomes isolated
from LNCaP cells. We compared two replicates of the same
exosome preparations from VCaP and from LNCaP cells,
respectively, and identified exosome-bound sequences by
NGS (Figure 2A). Supplementary Figure S3 shows the nor-
malized read counts after probing of the round 5 library on
VCaP and LNCaP exosomes that resulted in an averaged
normalized count of at least 500 for sequences recovered
from VCaP exosomes and at least a 4-fold higher recovery
of sequences fromVCaP exosomes compared to LNCaP ex-
osomes. As expected, binding of ssODNs to replicates of
the same exosome type resulted in a low degree of scatter-
ing of individual sequences, each of which is represented by
a black dot (Figure 2A, upper left panel for intra VCaP,
lowest panel for intra LNCaP). When counts of sequences
bound to VCaP exosomes were compared to LNCaP ex-
osomes, a high degree of scattering was observed, indica-
tive of differential binding of ssODNs to different sam-
ples and various underlying sample profiles (Figure 2A, yel-
low frame). The lower left panel in Figure 2A (red frame)
shows a magnification of the counts of sequences bound to
VCaP exosome replicate 2 on the vertical axis, versus the
counts of sequences bound to LNCaP exosome replicate 1
on the horizontal axis.We selected those sequences in which
counts were most highly overrepresented (blue) compared
to the orange line that indicates zero-deviation and three
sequences that showed the strongest level of underrepresen-
tation. These sequences should represent distinct ssODNs
that identify biological differences between the two classes
of exosomes being compared.
Nine of the exosome-bound synthetic sequences (Figure
2B), indicated as blue dots, were individually synthesized
and subjected to further analysis. The randomized regions
of sequences 1–9 appear to be lower in their C- and A-
content than in theirG- andT-content (Supplementary Fig-
ure S4A) whereas the distribution of the four bases after en-
richment round 1 is more equal than after VCaP exosome
probing using the round 5 library (Supplementary Figure
S4B). Moreover, there is a shift in base-distribution from
round 1 to round 5 toward a higher content of T and a
low content of A, whereas the G/C-content remains more
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Figure 2. Sequence identification and verification. (A) Library after five rounds of enrichment was used to probe exosomes from VCaP and LNCaP cells
in order to identify individual ODNs that bound preferably to exosomes from VCaP cells (blue). Per exosome type two probing reactions (replicates 1 and
2) were performed and bound ODNs were identified by NGS; each dot represents one unique sequence with counts from different samples on both axes.
Yellow frame: comparison of counts from VCaP exosome replicates 1 and 2 with LNCaP exosome replicates 1 and 2. Red frame: magnification of the
VCaP exosome replicate 2 versus LNCaP exosome replicate 1 distribution of counts. A higher degree of scattering indicates the selection of sequences with
a higher affinity to one or the other sample. For details on the NGS results see Supplementary Figure S3. (B) Sequences were resynthesized and binding
of co-precipitated ODNs to VCaP exosomes was verified by qPCR. Sequences of the ssDNA clones 1–9. Italic: 5′-primer binding site; regular: 3′-primer
binding site; bold: variable region. All nine sequences have the potential of forming G-quadruplex structures according to QGRS-mapper (68). For the
related reverse complementary and scrambled versions of sequences 1–9 see Supplementary Table S1. (C) Left panel: Comparison of the averages across
three lots of exosomes by binding of a pool of nine unique sequences (blue; represented as blue dots in A), a pool of their scrambled versions (black), and
a pool of their reverse complements (red) by qPCR. Binding is expressed as the recovered copies per sequence from 2 g of exosomes as determined by
the BCA assay. Error bars: S.D.; n= 3. Right panel: Relative recovery across all exosome lots with selected sequences normalized to the indicated negative
controls. Ratio: Fold-change between relative recoveries between VCaP versus LNCaP exosomes. Values of individual lots and the standards of pools in
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of VCaP exosome binding, we prepared three samples of ex-
osomes from independent batches of VCaP cells and three
samples of exosomes from independent batches of LNCaP
cells. The nine VCaP-binding ssODNs shown in Figure 2B
were resynthesized and pooled in equimolar quantities. Af-
ter binding of the pooled sequences to the three batches of
exosome preparations, removal of unbound, and recovery
of bound sequences, the recovered ssODNs were subjected
to qPCR analysis (Figure 2C). As negative controls, syn-
thetic versions of the scrambled and the reverse comple-
mentary sequences (Supplementary Table S1), respectively,
of each of the nine ssODNs were also pooled in equimolar
quantities. The recovered copies per species were generally
higher for the pool of selected sequences as compared to the
pools of control sequences (Figure 2C, left panel; Supple-
mentary Figure S5). However, the values of relative recov-
ery obtained by normalization of the recovered copies per
species of the pool of selected sequences versus either the
pool of their scrambled or the pool of their reverse com-
plement versions, respectively, was 2.3- or 2.8-fold higher
for VCaP versus LNCaP exosomes, respectively (Figure 2C,
right panel).
Together, these data not only confirm the high repro-
ducibility of the VCaP cell exosome-specific ssODNs within
batches of VCaP cell exosomes that was already evident
from the low scattering of NGS-data for two VCaP cell ex-
osome probing replicates (Figure 2A, upper left panel), but
also show that the recovery as analyzed by qPCR is specific
for VCaP versus LNCaP cell exosomes. The sequences se-
lected for binding to VCaP cell exosomes showed a consid-
erably lower recovery rate when bound to and eluted from
exosomes from LNCaP cells. Moreover, binding to VCaP
cells is highly sequence-specific as indicated by the marginal
recovery of the pool of reverse complementary sequences
after incubation with exosomes from VCaP and LNCaP
cells.
Having shown that the pooled nine sequences (Figure
2B) can discriminate between VCaP and LNCaP cell exo-
somes, we tested the ability of individual sequences to bind
to VCaP exosomes by qPCR (Figure 3A). We recovered be-
tween 4 × 106 and 5 × 106 copies per sequence in case of
sequences 1, 6, 8 and 9, between 7 × 106 and 1.5 × 107 for
sequences 2–5, and up to >2 × 107 for Sequence 7. The re-
verse complement sequenceswere lower in that value, except
for sequences 1, 6 and 9, where the RC versions gave higher
values than the selected sequences. Except for sequence 9,
all scrambled versions were lower than their respective se-
lected sequences. Together, the data indicate that sequences
1–8 that exhibit high counts in VCaP versus LNCaP (Fig-
ure 1A, red frame, blue dots) do show specific interaction
with VCaP cell derived exosomes, when compared to their
scrambled versions.
Target Identification
We next sought to identify binding partners of ssODNs
bound to VCaP cell exosomes and chose Sequence 7 as a
pull-down bait (15,16), as this sequence showed the high-
est level of recovered copies per sequence from the qPCR
analysis (Figure 3A). These results are unlikely to be bi-
ased by the formation of primer-dimers since we have used
the same primers for all sequences. If there were such a
bias, it should affect all sequences in the same way. A bi-
otinylated version of Sequence 7 was synthesized, immo-
bilized on streptavidin-coated Dynabeads™ and incubated
with VCaP exosomes. Unbound exosomes were removed
by washing; the bound exosomes were lysed with deter-
gent directly on the beads, followed by elution of the pro-
teins (Figure 3B) from the magnetic beads. The eluted pro-
teins were subjected to polyacrylamide gel electrophoresis
(Figure 3B); lane 2, shows the proteins that bound to Se-
quence 7, whereas lane 1 is the negative control without
DNA (no ssODN control), and lane 3 the negative con-
trol with the reverse complement Sequence 7 DNA (Se-
quence 7RC), which was chosen over the scrambled version
as it provides a more stringent control. Lanes were excised
from the gel, digested with trypsin, and subjected to LC-
MS/MS analysis. Single replicates for each condition were
performed.
The result of the mass-spectrometric analysis of pro-
tein binding partners of the VCaP cell exosome-specific
ssODN Sequence 7 is listed in Table 1 and includes pro-
teins that were either unique to Sequence 7 or showed higher
abundance (>2.5-fold) when bound to Sequence 7 com-
pared to the reverse complement of Sequence 7 or to the
no ssODN control beads. Cellular component Gene On-
tology (GO) enrichment analysis identified 16 of the 21
proteins as known to be associated with exosomes (Fig-
ure 3C, green circles). Protein pathway analysis was per-
formedwith the Reactome pathway knowledgebase (17,18).
Reactome pathway enrichment analysis revealed eight pro-
teins enriched in the ‘vesicle-mediated transport pathway’
(Figure 3C, yellow), six of which, CHMP2A, CHMP1B,
CHMP4B, CHMP4C, VPS28, and MVB12A were specific
to the ‘Endosomal Sorting Complex Required For Trans-
port (ESCRT)’ pathway (Figure 3C, red). The ESCRT ma-
chinery is a high molecular weight multi-protein complex
that participates in late endosome sorting and exosome
biogenesis (19). Protein–protein interactions within these
pathways were analyzed by the STRING database version
10.5 (string-db.org) that assesses direct (physical) and in-
direct (functional) associations (20). Several of the identi-
fied proteins, were also known or predicted to interact with
the ESCRT complex (SH3GL1, Syntenin-1) (Figure 3C),
connected through Alix (detected by MS but not necessar-
ily enriched by Sequence 7), or through TSG101 (detected
by MS but not differentially). Reactome pathway analysis
also found proteins enriched in the ‘Metabolism of RNA’
pathway, including YBX1/YB-1, PTBP1, CPSF5, CPSF7,
RPL30 andRPLP1. Two additional RNAbinding proteins,
RBM3 and eEF1A2, were also identified (white circles).
YBX1/YB-1 was not annotated by the STRING database
as interacting with TSG101, but it has been detected as
bound to TSG101 through ubiquitin linkages on YBX1
leading to its increased secretion (21), potentially linking
these networks together (Figure 3C, red dashed line). A
functional link between YBX1 and eEF1A2 has been pro-
posed based on the interaction of YBX1 and the mRNA
of eEF1A2 (Figure 3C, red dashed line) (22). Many of the
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Figure 3. Target ID. (A) Binding of nine unique sequences (represented as blue dots in 2A) to exosomes from VCaP cells by qPCR; blue bars represent
the nine selected sequences. Sequence 7 shows the highest absolute recovery, and was used for target ID; black bars: scrambled versions 1 of the respective
sequences; red bars: reverse complement versions of the respective sequences. Error bars: S.D.; n= 3. Binding is expressed as recovered copies per sequence
from 2 g of exosomes as determined by the BCA assay. (B) Affinity purification of target proteins bound to biotinylated Sequence 7 in combination
with LC-MS/MS detection identified exosomal binding partners of the aptamer. The gel in red boxes was used for digestion and mass spec analysis. Lane
1: no DNA control; bare beads. Lane 2: pull-down with Sequence 7. Lane 3: pull-down with reverse complement of Sequence 7. (C) Reactome pathway
enrichment and STRING 10.5 database analyses of the protein-protein networks of proteins that bound to Sequence 7 with ≥2.5-fold higher abundance
than to the Sequence 7RC or to the no oligo bead only control. Black lines: direct or indirect protein-protein associations, edge confidence level high (0.7)
to highest (0.9); blue lines: confidence level medium (0.4); red lines: confidence level low (0.15); red dotted lines: interaction not denoted by Reactome
or STRING 10.5, but by references (21) for TSG101/YBX1 and (22) for YBX1/eEF1A2 mRNA. Circles represent proteins, protein isoforms, or PTMs
produced by a single, protein-coding gene locus. Green circles: proteins associated with exosomes; yellow circles: enriched in the endocytic pathway; red
circles: annotated by Reactome or STRING as part of the ESCRT complex. White circles: RNA binding proteins. Pale colored circles: connected through
Alix (detected by MS but not necessarily enriched by Sequence 7). Proteins shown in boldface are associated with prostate cancer. CXCL11 (grey circle) is
not part of any classification.
prostate cancer, including CHMP4C (41), Syntenin-1 (35),
YBX1 (11), PTBP1/hnRNP-1 (11), RBM3 (23), eEF1A2
(24), SH3GL1 (25), S100A8 (26),HBA2 (27), CXCL11 (28),
LAMA3 (29) and TSG101 (30) shown in bold in Figure 3C.
In addition, CPSF5, a splicing factor critical for gene si-
lencing in hepatocellular carcinoma (31) was identified, and
DNAJA2, a protein that belongs to the heat shock protein
familyHSP40 and acts as a co-chaperone ofHSP70was also
found.
Verification and characterization of targets affinity purified
with Sequence 7
To further verify the identified targets and to test for dif-
ferent protein levels in exosomes isolated from VCaP ver-
sus LNCaP cells, we compared their relative abundances in
exosomes from VCaP cells with those from LNCaP cells
by western blotting (Figure 4A) and quantified their rel-
ative abundance in these two types of exosomes (Figure
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CHMP1B Charged multivesicular body protein 1b Part of ESCRT machinery that plays role in
exosome biogenesis. Identified in exosomes
from expressed prostatic secretions
Yes (60–64)
CHMP2A No
CHMP4B Charged multivesicular body protein 4b Yes
CHMP4C Charged multivesicular body protein 4c Yes
MVB12A Multivesicular body subunit 12A Yes
SH3GL1 Endophilin-A2 No
VPS28 Vacuolar protein sorting-associated protein
28 homolog
Yes
Syntenin-1 Syntenin-1 Associated to ESCRT machinery that plays
role in exosome and prostasome biogenesis
Yes (60,62,63,65)
YBX1 Nuclease-sensitive element-binding protein
1
Connected to ESCRT-1 complex by
interacting with TSG101 Marker in CRPC
and role in resistance to enzalutamide
Yes (46)
RPLP1 60S acidic ribosomal protein P1 No
RBM3 RNA-binding protein 3 No
RPL30 60S ribosomal protein L30 No
HBA2 Hemoglobin subunit alpha No
S100A8 Protein S100-A8 No
CXCL11 C-X-C motif chemokine 11 Increased gene expression in prostate cancer No (28)
DNAJA2 DnaJ heat shock protein family (Hsp40)
member A2
Upregulated in spermatocytes; close
homolog of DNAJA1, which is involved in
spermatogenesis and AR signaling
Yes (48,49)
PTBP1 Polypyrimidine tract-binding protein 1,
hnRNP-1
Cancer associated splicing factor. Known
association with breast tumorigenesis;
required for tumor cell growth
Yes (66)
eEF1A2 Elongation factor 1-alpha 2 Promotes proliferation and inhibits
apoptosis in prostate cancer
Yes (67)
LAMA3 Laminin subunit alpha-3 Yes
CPSF5/
NUDT21
Cleavage and polyadenylation specificity
factor subunit 5
Yes
CPSF7 Cleavage and polyadenylation specificity
factor subunit 7
No
aAdditional MS data are listed in Supplementary Table S2.
comprising the ESCRT-complex, or being associated with
it, namely CHMP1B, CHMP4B, CHMP4C, Syntenin-1,
and YBX1 showed considerably higher abundance in ex-
osomes from VCaP cells than in exosomes from LNCaP
cells. TSG101 is a component of the ESCRTmachinery and
an established exosomal marker in prostate cancer (32). We
consistently found TSG101 to be present at similar levels
in exosomes from both cell lines and thus used this marker
for quantification by stripping each respective western blot
and re-blotting them with a TSG101 specific antibody (Fig-
ure 4A). Similar levels of TSG101 were observed for all an-
alyzed blots, thus confirming equal protein loading and the
elevated levels of abundance of the tested proteins in exo-
somes from VCaP cells versus LNCaP cells. Since TSG101
is a component of the ESCRT machinery, equal protein
loading was also confirmed by staining with MemCode®
Reversible Protein Stain (ThermoFisher Scientific) of each
blot (data not shown). Among the 21 proteins listed in Table
1, nine were disqualified due to unreliable protein detection
by the respective antibodies, precluding reliable quantitative
evaluation.
We next determined the intensity ratios between the
twelve marker proteins and their respective TSG101 load-
ing controls from multiple experiments (n ≥ 2) by densito-
metry. This quantification revealed that all proteins, except
MVB12A, eEF1A2, LAMA3 and VPS28 are present at el-
evated levels in VCaP cells as compared to LNCaP cells.
Similar to TSG101, the levels ofMVB12A, a TSG101 inter-
acting protein and also a member of the ESCRT-I complex
(34), LAMA3, a protein not known to be associated with
the ESCRT complex, and eEF1A2, were approximately
equal (Figure 4B) in both cell line exosomes. The most
marked difference between levels was found for Syntenin-
1 (>10-fold). DNAJA2, CPSF5, YBX1, CHMP1B and
CHMP4B showed a 6–7-fold higher level in VCaP cell ex-
osomes than in exosomes from LNCaP cells. A 4–5-fold
higher level in exosomes from VCaP cells compared to
LNCaP cells was observed for CHMP4C. Between 2- and
3-fold higher levels in VCaP versus LNCaP exosomes was
measured for PTBP1. VPS28 exhibited rather high fluctua-
tion in detection levels between experimental replicates, re-
sulting in rather high experimental error, making it unclear
as to whether there are differences in its detection levels be-
tween exosomes from VCaP versus LNCaP cells.
Sequence 7 binds specifically to YBX1
To determine the direct binding partner among the proteins
that were affinity purified with Sequence 7 we performed
enzyme-linked oligonucleotide assays (ELONAs). Recom-
binant purified candidate target proteins were immobilized
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Figure 4. Differential detection of identified proteins in VCaP vs LNCaP
exosomes by western blotting. (A) Of the 12 proteins tested (CHMP1B,
CHMP4B, CHMP4C, CPSF5, DNAJA2, PTBP1, Syntenin-1 and YBX1
all exhibit higher expression in exosomes from VCaP cells (VCaP) com-
pared to exosomes from LNCaP cells (LNCaP) as quantified by the inten-
sity ratios of targets to the respective TSG101 loading and transfer con-
trols. Only eEF1A2, LAMA3 and MVB12A showed similar expression
levels in VCaP and LNCaP exosomes. (B) Relative quantification of inten-
sities from several western blot experiments (VCaP exosomes: dark bars;
LNCaP exosomes: light bars) in relation to the respective TSG101 inten-
sities. CHMP1B: n = 4; CHMP4B: n = 2; CHMP4C: n = 2; CPSF5: n
= 2; DNAJA2: n = 3; EEF1A2: n = 2; LAMA3: n = 2; MVB12A: n =
2; PTBP1: n = 2; Syntenin-1: n = 2; VPS28: n = 4; YBX1: n = 2. Error
bars: mean ± S.D. All proteins verified by western blotting are shown in
italic in Figure 3C. We tested all proteins listed in Table 1 and Figure 3C,
respectively, but obtained ambiguous results due to insufficient antibody
specificity (data are not shown).
with streptavidin-poly HRP (SA-poly HRP), and quanti-
fied by measuring the absorbance at 450–540 nm (Figure
5A). The reverse complementary ssODNof Sequence 7 (Se-
quence 7RC) served as a negative control. For comparison
and to ensure protein integrity, each of the immobilized tar-
gets was independently confirmed by an enzyme-linked im-
munosorbent assay (ELISA), using the respective target-
specific antibody (Supplementary Figure S6).
Among all 21 proteins tested, a strong signal specific for
Sequence 7 was obtained only with recombinant YBX1.
Sequence 7RC gave a considerably weaker signal with
YBX1. In the case of RBM3, Sequence 7 yielded a sig-
nal that was comparative to that obtained for the com-
bination YBX1/Sequence 7RC, whereas the combination
RBM3/Sequence 7RC was negative (Figure 5A). These
results point to YBX1 as the direct Sequence 7 target.
To quantify these initial binding data, we performed an
ELONA titration using a fixed concentration of 10 nM
YBX1 and increasing concentrations of Sequence 7 (Fig-
ure 5B). Assuming the curve to be fully saturated at 3.0
absorbance with half-maximal 1.5 absorbance, a KD of ap-
proximately 3.0 nM can be estimated. For comparison, the
same experimentwas also carried out usingRBM3at 10 nM
fixed concentration. Sequence 7RC and no aptamer, respec-
tively, served as negative controls for both proteins. Only
with YBX1 a saturating binding curve was obtained with
Sequence 7. Aweak, but not saturating signal with flat slope
was obtained with the combination YBX1/Sequence 7RC,
whereas an even flatter slope was observed for the combi-
nation RBM3/Sequence 7. No changes in absorbance were
seen for all other negative control experiments even at the
highest ssODN concentrations of 20 nM. Taken together,
these data confirm YBX1 as the direct target of Sequence
7.
To investigate the binding behavior of sequences 1–6,
8 and 9 in comparison to Sequence 7 toward YBX1 we
carried out an ELONA. As controls the respective reverse
complements, and the respective scrambled versions of se-
quences 1–9 were also tested (Figure 5D). Except for se-
quence 1, all other sequences exhibited high levels of ab-
sorbance in the ELONA, with sequences 5, 7 and 8 yield-
ing the highest absolute values. The scrambled version 1 of
sequences 3–6 and 8 all showed considerably lower bind-
ing to YBX1, in contrast to those of sequences 2 and 7,
which were equal to the selected sequences. We therefore
designed another scrambled version for these two sequences
and found the scrambled version 2 no longer bind to YBX1.
The reverse complement versions exhibited reduced or low-
level binding, except for sequences 1, 2 and 6. Together, the
ELONA study indicates that most of the nine sequences do
interact with YBX1, at different levels and with different se-
lectivity with respect to their control sequences.
Sequence 7 specifically captures exosomes fromVCaPbut not
LNCaP cell culture media
To test whether Sequence 7 is capable of specifically captur-
ing VCaP but not LNCaP cell-derived exosomes, pull-down
experiments were carried out (Supplementary Data Set S7).
We grew VCaP or LNCaP cells separately in exosome-
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Figure 5. Direct ELONA experiments to identify the Sequence 7-bound target protein among a set of recombinant proteins. (A) Absorbance levels of
horseradish peroxidase (HRP) activity using 10 nM of the indicated recombinant proteins detected by 20 nM of biotinylated Sequence 7 or Sequence 7RC
premixed with streptavidin-poly-HRP. Error bars: S.D.; n = 3 for all proteins except for YBX1 (n = 6). (B) Titration of 10 nM YBX1 with increasing
concentrations of Sequence 7 (blue diamonds) versus Sequence 7RC (red squares), and no ssODN (green triangles). The no protein/Sequence 7 (purple
cross) and no protein/Sequence 7RC (blue star) controls did not change with concentration. (C) The same experiment carried out using 10 nM RBM3
instead of YBX1. Assuming the curve to be fully saturated at 3.0 absorbance with half-maximal 1.5 absorbance, a KD of approximately 3.0 nM can be
estimated. (D) ELONA performed for each of the nine sequences and their respective scrambled version 1 on 10 nM YBX1. Sequences 2 and 7 were also
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Figure 6. Composition of the ESCRT Machinery. Proteins in red circles were found to be present at higher abundance in exosomes from VCaP cells
compared to exosomes from LNCaP cells as part of this study. Proteins in blue circles were found to be present in similar quantities in both types of
exosomes. Adapted with permission from (19). Copyright 2017 Elsevier.
were present in the same volume of cell culture media super-
natant from both VCaP and LNCaP cells, we performed a
classic immunoprecipitation (IP) followed by western blot
capturing exosomes with an anti-CD9 biotinylated anti-
body and probing for TSG101 using an anti-TSG101 an-
tibody. Aptamer pull-downs (AP) were done from the same
volume of cell culture media supernatant capturing with Se-
quence 7, Sequence 7scr, Sequence 7RC, and beads-only
and probing for TSG101 with an anti-TSG101 antibody.
Three independent experiments were carried out, the results
of which are described and discussed in detail in the Supple-
mentary Data Set S7. These data show that VCaP exosomes
and not LNCaP exosomes can be pulled down specifically
with Sequence 7. The data set also shows that Sequence 7
can pull downmore exosomes fromVCaP supernatant than
its control sequences 7RC and 7scr, but the absolute levels
of these pulldowns are variable in the three independent ex-
periments, and so are the differences in the levels between
Sequence 7 and its negative control sequences. Because the
aptamers were selected on purified exosomes not in cell cul-
ture media, the variability between Sequence 7 and its neg-
ative control sequences seen in the three independent ex-
periments shown in Supplementary Data Set 7 is not too
surprising given that aptamers tend to work best under the
conditions under which they were selected.
DISCUSSION
We carried out an in vitro selection using a ssODN-library
to target exosomes from the prostate cancer cell line VCaP,
which led to a set of enriched sequences that discriminate
between exosomes from VCaP and LNCaP cells –subtypes
of androgen receptor positive prostate cancer cells. VCaP
was first described in 2001 as a prostate cancer cell line that
was derived from a vertebral metastatic lesion to a lum-
bar vertebral body of a patient with hormone-refractory
prostate cancer (33). VCaP cells differ morphologically
from LNCaP cells with more pronounced dendritic exten-
sions whereas LNCaP are adherent epithelial cells grow-
ing in aggregates and as single cells (34). The employed se-
lection scheme is related to our recently described molecu-
lar profiling technology called ‘Adaptive dynamic artificial
polyligand targeting’ (ADAPT), a platform that combines
aptamer selections with next generation sequencing and tar-
get identification (11). ADAPT can be deployed against
multiple cancer types in various biological matrices, and
offers broad potential applications in biomarker discovery.
Here we show that ADAPT could not only discriminate be-
tween cancer types but between subtypes of a specific lin-
eage.
Among the nine enriched sequences, we found Sequence
7 to be the sequence with the highest relative recovery in
qPCR, and used this sequence for target identification by
affinity purification and mass spectrometry. Most of the
identified proteins associated with Sequence 7 are known
to be involved in the formation of the endosomal sorting
complexes required for transport (ESCRT)machinery (Fig-
ure 6). The ESCRT machinery is a large multi-component
assembly of proteins and consists of the sub-complexes I,
II and III (19). Its main biological function involves cel-
lular cargo transportation; including remodeling of early
endosome membranes for ubiquitinylated receptor sorting
(35), membrane bending, scission and repair (36,37), endo-
somal sorting and intraluminal vesicle formation (38), and
cell-to-cell communication by ecto- and exosomal secretion
(19,39,40). These activities imply the ESCRT complex as a
central gatekeeper of cargo flow toward degradation (41).
Moreover, several ESCRT proteins have been implicated in
playing a role in cancer (40), and recently in prostate can-
cer (42). Specifically, the latter study showed that the farne-
syltransferase inhibitor manumycin A suppresses exosome
biogenesis and secretion in the castration-resistant prostate
cancer cell line C4–2B. This effect was partly mediated by
ERK-dependent inhibition of the oncogenic splicing factor
hnRNP-H1. Another study (43) identified hnRNP-L as a
potential hub protein for prostate cancer, a known interac-
tor of PTBP1/hnRNP-1 (44) that we found here to be 2- to
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PTBP1/hnRNP-1 protein recruitment to the AR gene was
previously observed in VCaP cells under ADT conditions
induced by treatment with the non-steroidal anti-androgen
Enzalutamide, suggesting a role in AR and AR-V7 splicing
(13). The transcriptional regulator Y-box binding protein-1
YBX1 was also found associated with core splicing com-
ponents in exosomes from Ras-transformed MDCK cells
following epithelial-mesenchymal transition (EMT) (45);
we detected 6- to 7-fold higher YBX1 levels in exosomes
from VCaP versus LNCaP cells. YBX1 associates with the
ESCRT-1 complex by interacting with TSG101 when ubiq-
uitinylated (21), and was recently shown to be required for
developing resistance against Enzalutamide treatment in
prostate cancers expressing AR-V7 (46). Thus, YBX1 was
suggested as a target for inhibition to prevent the develop-
ment of castration resistance where splice variants are ex-
pressed that render AR inhibitors such as Enzalutamide in-
effective. It was also suggested thatYBX1might be a predic-
tive biomarker for ADT in metastatic prostate cancer (46).
Sequence 7 is not the only aptamer identified in this study
that binds to YBX1. Sequences 2–6, 8 and, to a lower ex-
tent sequence 9 also bind to YBX1, whereas sequence 1
does not. This finding is not unexpected since all of the
nine sequences share a related G-rich motif (Supplemen-
tary Figure S4A). YBX1 was found to also bind to tiR-
NAs that are able to assemble G-quadruplex-like structures
at oligoguanine-motifs they usually contain at their 5′-ends
(47). The differences of each individual sequence in their
YBX1 binding as determined by an ELONA (Figure 5D)
may be the result of differences in the G-rich motif. On the
other hand, one may hypothesize that in the context of the
ESCRT complex each sequence binds to YBX1 as its pri-
mary target, but might also sense slight differences in the
chemical environment of YBX1 resulting from the proteins
in the complex that are in close proximity to YBX1.
DNAJA2 was identified as another highly-upregulated
protein in exosomes from VCaP cells compared to LNCaP
exosomes. This protein belongs to the HSP40-homologous
class of co-chaperones and was found to be upregu-
lated in spermatocytes (48). It shares high homology with
DNAJA1, which is involved in spermatogenesis and AR
signaling (49). We did not find any reports suggesting that
DNAJA2 directly interacts with the ESCRT machinery, or
any members of the ESCRT complexes in VCaP. How-
ever, LNCaP95 is a prostate cancer cell line that also ex-
pressesAR-V7 associatedwith increased resistance toADT,
like VCaP (but unlike LNCaP). In LNCaP95 cells, an anti-
HSP70 antibody immunoprecipitated DNAJA3 along with
YBX1 and CPSF5 (50). DNAJA3 is highly homologous to
DNAJA2, and YBX1 and CPSF5 were both also found in
our study. Moreover, DNAJA2 is involved in Ago2-RNA
silencing complex assembly (Ago2-RISC) (51) which has
been shown to modulate the splicing of HIV-1 viral tran-
scripts independent of their miRNA binding function, as
well as having a role in coupling of chromatin silencing and
alternative splicing (52).
Syntenin-1 and the CHMP-proteins 1B, 4B and 4C also
showed considerably higher levels in exosomes from VCaP
cells compared to those from LNCaP cells. These proteins
are well-documented members of the ESCRT machinery
(Figure 6). Interestingly, Chiasserini et al. (53) recently iden-
tified two populations of prostasomes, extracellular vesi-
cles that are secreted by epithelial cells of the prostate (2).
In one of the prostasome populations the ESCRT proteins
Alix, Syntenin-1, and TSG101 were overrepresented ∼3-
fold, which is within the order of magnitude of the differ-
ential levels of abundance of Syntenin-1 in VCaP cell exo-
somes that we observe in this study when using Sequence 7
pull-downs compared to the Sequence 7 negative control se-
quences. TSG101, VPS28 and CHMP4B were also among
the proteins that were recently found to be essentially re-
quired for restricting the constitutive signaling of NF-B in
HEK293 cells (41).
Most of the proteins that were affinity purified with Se-
quence 7 constitute known members of the ESCRT com-
plex, with the direct target of Sequence 7 being YBX1, pre-
sumably bound by an aptameric binding mechanism. To
our knowledge, aptamers that selectively target the ESCRT
complex on exosomes associated with a specific prostate
cancer cell line, or individual members thereof, have not
been described. The only example that relates aptamer
technology to prostate cancer is the anti-PSMA aptamer
that binds the human prostate-specific membrane antigen
PSMA, and was shown to specifically target prostate tumor
cells (54). When this aptamer was conjugated to the toxin
gelonin, the aptamer ‘escorted’ the toxin to tumor cells that
are characterized by PSMA overexpression (55,56). Others
have used this aptamer for cell-type specific delivery of siR-
NAs (56), cis-Pt(IV)-prodrug nanoparticles (57), or quan-
tum dots (58). Because these aptamers can be used to target
drugs to specific cell types they are commonly designated
as ‘escort’-aptamers, but they are completely unrelated to
targeting the ESCRT-machinery.
This study demonstrates that the ADAPT platform can
lead to the identification of differences in protein expres-
sion patterns between exosomes from two related prostate
cancer cell lines VCaP and LNCaP. Sequence 7 is likely to
bind the ESCRT complex by a direct aptameric interaction
withYBX1 associated with amulticomponent protein com-
plex. There is no biomarker-guided strategy for advanced
prostate cancer treatment except up-front ADT.
Taken together, our study shows that ADAPT is a pow-
erful method that allows for the enrichment of polyligands
that can distinguish even between different subpopulations
of the same disease. Our analysis and characterization re-
vealed differences in the composition of ESCRT and as-
sociated complexes between exosomes derived from VCaP
and LNCaP cells. Several of the ESCRT-comprising pro-
teins appear to be present at similar or equal levels, while
others clearly show elevated levels in VCaP cell exosomes.
Whether these differences qualify the respective proteins as
novel biomarkers for these different prostate cancers, will be
the subject of further investigation.
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